Table 3.
Disease management and optimal responses in patients with iMCD-NOS
| iMCD-IPL (n=101) | iMCD-NOS w/o IPL (n=115) | P | |
|---|---|---|---|
|
| |||
| First-line treatment | 0.073 | ||
| Thalidomide-based | 50/101 (50%) | 51/115 (44%) | |
| Bortezomib-based | 20/101 (20%) | 22/115 (19%) | |
| Tocilizumab | 5/101 (5%) | 2/115 (2%) | |
| Siltuximab | 6/101 (6%) | 1/115 (1%) | |
| Rituximab-based | 5/101 (5%) | 7/115 (6%) | |
| CHOP | 9/101 (9%) | 24/115 (21%) | |
| Remission after first-line treatment | 72/98 (73%) | 68/99 (69%) | 0.459 |
| Ever response to thalidomide | 0.043 | ||
| Remission | 50/64 (78%) | 31/51 (61%) | |
| Failure | 14/64 (22%) | 20/51 (39%) | |
| Ever response to bortezomib | 0.908 | ||
| Remission | 35/43 (81%) | 37/46 (80%) | |
| Failure | 8/43 (19%) | 9/46 (20%) | |
| Ever response to rituximab | 0.397 | ||
| Remission | 5/10 (50%) | 11/15 (73%) | |
| Failure | 5/10 (50%) | 4/15 (27%) | |
| Thalidomide use in | 0.006 | ||
| First-line | 50/64 (78%) | 49/51 (96%) | |
| Later-line | 14/64 (22%) | 2/51 (4%) | |
| Bortezomib use in | 0.621 | ||
| First-line | 20/43 (47%) | 19/46 (41%) | |
| Later-line | 23/43 (53%) | 27/46 (59%) | |
| Rituximab use in | 0.697 | ||
| First-line | 5/10 (50%) | 6/15 (40%) | |
| Later-line | 5/10 (50%) | 9/15 (60%) | |
Abbreviations: CHOP, cyclophosphamide, doxorubicin, vincristine, and prednisone
Significant P values are in bold.